United States-based Kala Pharmaceuticals has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for the new drug application (NDA) for KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease, it was reported on Friday.
The US FDA has indicated that efficacy data from an additional clinical trial will be required to support a resubmission. The company continues to enrol patients in its ongoing STRIDE three (STRIDE – Short Term Relief In Dry Eye) Phase three clinical trial, and expects this trial will serve as the basis of its response to the CRL. The company is aiming at top line data from STRIDE three by the end of 2019 and resubmission of the NDA application during the first half of 2020. It believes this resubmission is to be subjected to a six-month review under the Prescription Drug User Fee Act. The STRIDE three trial design indicates specific modifications to the inclusion and exclusion criteria of the company's earlier trials of KPI-121 0.25 percent, which were implemented to improve the probability of success.
Kim Brazzell, chief medical officer of Kala Pharmaceuticals, said, 'We remain confident in the potential of KPI-121 0.25 percent to be the first approved product for the temporary relief of the signs and symptoms of dry eye disease. We look forward to reporting data from STRIDE 3 and resubmitting the NDA with the goal of obtaining approval and being able to offer KPI-121 0.25% to the millions of patients with dry eye disease.'
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT